Knowledge-accelerated drug development
Сохранить в:
| Опубликовано в:: | Pharmaceutical Executive vol. 18, no. 4 (Apr 1998), p. 88-93 |
|---|---|
| Главный автор: | |
| Другие авторы: | |
| Опубликовано: |
MultiMedia Healthcare Inc.
|
| Предметы: | |
| Online-ссылка: | Citation/Abstract Full Text |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 216425825 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 0279-6570 | ||
| 022 | |a 2150-735X | ||
| 035 | |a 216425825 | ||
| 045 | 2 | |b d19980401 |b d19980430 | |
| 084 | |a 01618095 | ||
| 084 | |a 13756 |2 nlm | ||
| 100 | 1 | |a Mamelok, Richard D | |
| 245 | 1 | |a Knowledge-accelerated drug development | |
| 260 | |b MultiMedia Healthcare Inc. |c Apr 1998 | ||
| 513 | |a PERIODICAL | ||
| 520 | 3 | |a Knowledge-accelerated drug development is a step-by-step process that companies can adopt to take full advantage of state-of-the-art computer-assisted technology. At an operational level within projects, research teams can use knowledge-accelerated drug development to assess different trial designs by accounting for many more variables that affect outcome than traditional methods can accomplish. That allows the team to choose the best design. Moving from current clinical planning methodology to new technology that provides better assessments can occur in 4 sequential steps: 1. computer-based trials management, 2. computer-assisted trial design, 3. computer-assisted clinical program design, and 4. computer-assisted portfolio management. | |
| 651 | 4 | |a United States--US | |
| 653 | |a Clinical trials | ||
| 653 | |a Decision making | ||
| 653 | |a Methods | ||
| 653 | |a Guidelines | ||
| 653 | |a FDA approval | ||
| 653 | |a Project management | ||
| 653 | |a Pharmaceutical industry | ||
| 653 | |a Compliance | ||
| 653 | |a Computer based modeling | ||
| 653 | |a Research & development--R&D | ||
| 653 | |a Critical path | ||
| 653 | |a Portfolio management | ||
| 653 | |a Software | ||
| 653 | |a Teams | ||
| 653 | |a Planning | ||
| 653 | |a Knowledge | ||
| 653 | |a Cholesterol | ||
| 653 | |a Design | ||
| 653 | |a Drug dosages | ||
| 653 | |a Designers | ||
| 653 | |a Drug development | ||
| 700 | 1 | |a Olson, Camilla | |
| 773 | 0 | |t Pharmaceutical Executive |g vol. 18, no. 4 (Apr 1998), p. 88-93 | |
| 786 | 0 | |d ProQuest |t ABI/INFORM Global | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/216425825/abstract/embedded/75I98GEZK8WCJMPQ?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/216425825/fulltext/embedded/75I98GEZK8WCJMPQ?source=fedsrch |